Avid Bioservices, Inc.

Good day, ladies and gentlemen, and welcome to the Avid Bioservices Second Quarter Fiscal 2022 Financial Results Conference Call. At this time, all participants are in listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. As a reminder, this conference call may be recorded. I would now like to hand the conference over to Tim Brontz of Avid's Investor Relations Group. Please go ahead.

Thank you. Good afternoon, and thank you for joining us. On today's call, we have Nick Green, President and CEO, Dan Hart, Chief Financial Officer, and Matt Quitniak, AVID's Chief Commercial Officer. Today, we will be providing an overview of AVID Bioservices' contract development and manufacturing business, including updates on corporate activities and financial results for the quarter ended October 31st, 2021. After our prepared remarks, we will welcome your questions. Before we begin, I'd like to caution that comments made during this conference call today, December 7th, 2021, will contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning the current belief of the company, which involves a number of assumptions, risks, and uncertainties. Actual results could differ from these statements, and the company undertakes no obligation to revise or update any statement made today. I encourage you to review all of the company's filings with the Securities and Exchange Commission concerning these and other matters. Our earnings press release and this call will include discussion of certain non-GAAP information. You can find our earnings press release, including relevant non-GAAP reconciliations, on our corporate website at avidbio.com. With that, I will turn the call over to Nick Green, AVID's President and CEO.

Thank you, Tim, and thank you to everyone who has dialed in and to those participating today via webcast. I am pleased to announce another strong quarter at AVID. Beginning with our financial results, for the sixth quarter in a row, we have recorded an increase in revenues compared to the prior year period. On the new business front, our team signed numerous new clients and new orders, further strengthening our pipelines. Finally, with respect to operations, the company successfully completed its annual maintenance shutdowns and broke ground on the Myford South construction. Most significantly, the company recently announced its expansion into viral vector development and the manufacturing services for cell and gene therapy products. We believe this area offers significant opportunity for growth, and we are very excited to begin offering services to this sector. Before I turn the call over to Dan for a review of the financial results, I would first like to welcome Matt, Avid's new Chief Commercial Officer, to the call. Matt is an accomplished senior global sales executive with a proven track record of driving revenue growth. In his new role, he will be responsible for the continuing growth of Avid's business through the ongoing expansion of the company's commercial and clinical client base. We are extremely pleased to have Matt join our team and we look forward to working with him. Matt and I will provide additional details on business development and operations for the period, following an overview of our second quarter financial results. And for that, I'll turn the call over to Dan.